NCT04040322: A trial that was reported late by Civi Biopharma, Inc.
This trial has reported, although it was 1049 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04040322 |
|---|---|
| Title | A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 14, 2019 |
| Completion date | June 9, 2021 |
| Required reporting date | June 9, 2022, midnight |
| Actual reporting date | April 23, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 1049 |